Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

DOI record: { "DOI": "10.1186/s40360-024-00753-7", "ISSN": [ "2050-6511" ], "URL": "http://dx.doi.org/10.1186/s40360-024-00753-7", "abstract": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Monoclonal antibody therapy for Covid-19 springs up all over the world and get some efficiency. This research aims to explore the treating effect of BRII-196(Ambavirumab) plus BRII-198(Lomisivir) on Covid-19.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>In this retrospective cohort research, patients received standard care or plus BRII-196 /BRII-198 monoclonal antibodies. General comparison of clinical indexes and prognosis between Antibody Group and Control Group was made. Further, according to the antibody using time and patients’ condition, subgroups included Early antibody group, Late antibody group, Mild Antibody Group, Mild Control Group, Severe Antibody Group and Severe Control Group.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>Length of stay(LOS) and interval of Covid-19 nucleic acid from positive to negative of Antibody Group were 12.0(IQR 9.0–15.0) and 14.0(IQR 10.0–16.0) days, less than those(13.0 (IQR 11.0–18.0) and 15.0 (IQR 12.8–17.0) days) of Control Group(<jats:italic>p</jats:italic> = 0.004, <jats:italic>p</jats:italic> = 0.004). LOS(median 10days) of Early Antibody Group was the shortest, significantly shorter than that of Control Group (median 13days)(<jats:italic>p</jats:italic> &lt; 0.001). Interval(median 12days) of Covid-19 nucleic acid from positive to negative of Early Antibody Group also was significantly shorter than that of Control Group(median 15days) and Late Antibody Group(median 14days)(<jats:italic>p</jats:italic> = 0.001, <jats:italic>p</jats:italic> = 0.042). LOS(median 12days) and interval(median 13days) of Covid-19 nucleic acid from positive to negative of Mild Antibody Group was shorter than that of Mild Control Group(median 13days; median 14.5days)(<jats:italic>p</jats:italic> = 0.018, <jats:italic>p</jats:italic> = 0.033).</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusion</jats:title>\n <jats:p>The neutralizing antibody therapy, BRII-196 plus BRII-198 could shorten LOS and interval of Covid-19 nucleic acid from positive to negative. However, it didn’t show efficacy for improving clinical outcomes among severe or critical cases.</jats:p>\n </jats:sec>", "alternative-id": [ "753" ], "article-number": "29", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "15 July 2023" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "10 April 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "19 April 2024" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The study was followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975. The medical research record number is MR-50-20-002145 obtained from National Medical Research Registration and Filing System. Informed consent was obtained from all subjects or their legal guardians. The study was approved by the Hohhot First Hospital Research Ethics Commission on September 25th, 2022. Meanwhile it was also approved by Chongqing Public Health Treatment Center Research Ethics Commission." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "NA." }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Yalan", "given": "Qin", "sequence": "first" }, { "affiliation": [], "family": "Lingfang", "given": "Hao", "sequence": "additional" }, { "affiliation": [], "family": "Xisong", "given": "Liu", "sequence": "additional" }, { "affiliation": [], "family": "Run", "given": "Liang", "sequence": "additional" }, { "affiliation": [], "family": "Junjing", "given": "Zhang", "sequence": "additional" }, { "affiliation": [], "family": "An", "given": "Zhang’", "sequence": "additional" } ], "container-title": "BMC Pharmacology and Toxicology", "container-title-short": "BMC Pharmacol Toxicol", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 4, 19 ] ], "date-time": "2024-04-19T10:01:45Z", "timestamp": 1713520905000 }, "deposited": { "date-parts": [ [ 2024, 4, 19 ] ], "date-time": "2024-04-19T10:05:29Z", "timestamp": 1713521129000 }, "funder": [ { "award": [ "No.csct2020jscx-fyzxX0012" ], "name": "Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control" } ], "indexed": { "date-parts": [ [ 2024, 4, 20 ] ], "date-time": "2024-04-20T00:28:59Z", "timestamp": 1713572939229 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2024, 4, 19 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2024, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 4, 19 ] ], "date-time": "2024-04-19T00:00:00Z", "timestamp": 1713484800000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 4, 19 ] ], "date-time": "2024-04-19T00:00:00Z", "timestamp": 1713484800000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1186/s40360-024-00753-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1186/s40360-024-00753-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1186/s40360-024-00753-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1186", "published": { "date-parts": [ [ 2024, 4, 19 ] ] }, "published-online": { "date-parts": [ [ 2024, 4, 19 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.arcmed.2020.04.021", "author": "S Hanaei", "doi-asserted-by": "publisher", "first-page": "582", "journal-title": "Arch Med Res", "key": "753_CR1", "unstructured": "Hanaei S, Rezaei N. COVID-19: developing from an outbreak to a pandemic. Arch Med Res. 2020;51:582–4.", "volume": "51", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30183-5", "author": "C Huang", "doi-asserted-by": "publisher", "first-page": "497", "issue": "10223", "journal-title": "Lancet", "key": "753_CR2", "unstructured": "Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.", "volume": "395", "year": "2020" }, { "DOI": "10.1002/jmv.27588", "author": "Y Araf", "doi-asserted-by": "publisher", "first-page": "1825", "issue": "5", "journal-title": "J Med Virol", "key": "753_CR3", "unstructured": "Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825–32.", "volume": "94", "year": "2022" }, { "DOI": "10.1001/jamanetworkopen.2022.50647", "author": "JW Senefeld", "doi-asserted-by": "publisher", "first-page": "e2250647", "issue": "1", "journal-title": "JAMA Netw Open", "key": "753_CR4", "unstructured": "Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(1):e2250647.", "volume": "6", "year": "2023" }, { "DOI": "10.1056/NEJMoa2021436", "author": "P Horby", "doi-asserted-by": "publisher", "first-page": "693", "journal-title": "N Engl J Med", "key": "753_CR5", "unstructured": "Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704.", "volume": "384", "year": "2021" }, { "DOI": "10.37201/req/158.2021", "author": "A García-Lledó", "doi-asserted-by": "publisher", "first-page": "115", "issue": "2", "journal-title": "Rev Esp Quimioter", "key": "753_CR6", "unstructured": "García-Lledó A, Gómez-Pavón J, González D, Castillo J, et al. Pharmacological treatment of COVID-19: an opinion paper. Rev Esp Quimioter. 2022;35(2):115–30.", "volume": "35", "year": "2022" }, { "DOI": "10.1002/rmv.2231", "author": "D Focosi", "doi-asserted-by": "publisher", "first-page": "e2231", "issue": "6", "journal-title": "Rev Med Virol", "key": "753_CR7", "unstructured": "Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021;31(6):e2231.", "volume": "31", "year": "2021" }, { "DOI": "10.1038/s41467-020-20501-9", "author": "J Ge", "doi-asserted-by": "publisher", "first-page": "250", "issue": "1", "journal-title": "Nat Commun", "key": "753_CR8", "unstructured": "Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat Commun. 2021;12(1):250.", "volume": "12", "year": "2021" }, { "DOI": "10.3390/ijms21134782", "author": "A Allegra", "doi-asserted-by": "publisher", "first-page": "4782", "issue": "13", "journal-title": "Int J Mol Sci", "key": "753_CR9", "unstructured": "Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications. Int J Mol Sci. 2020;21(13):4782.", "volume": "21", "year": "2020" }, { "DOI": "10.1007/s11427-022-2215-6", "doi-asserted-by": "crossref", "key": "753_CR10", "unstructured": "Ling Z, Yi C, Sun X, Yang Z, Sun B. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Sci China Life Sci. 2022:1–21." }, { "key": "753_CR11", "unstructured": "Sisi S, Ruoke W, Qi Z. Zhang Linqi.Ambavirumab injection (BRII-196) and Romisisimab injection (BRII-198): China’s first independent intellectual property rights of neutralization and antibody combined therapy for COVID-19 [J]. Chin J Med. 2022,24(01):2–8." }, { "key": "753_CR12", "unstructured": "National Health Commission of China. New coronavirus pneumonia prevention and control program(9th ed). China Med,2022(04):481–7." }, { "DOI": "10.1371/journal.ppat.1008762", "author": "A Mittal", "doi-asserted-by": "publisher", "first-page": "e1008762", "issue": "8", "journal-title": "PLoS Pathog", "key": "753_CR13", "unstructured": "Mittal A, Manjunath K, Ranjan RK, et al. COVID-19 pandemic: insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog. 2020;16(8):e1008762.", "volume": "16", "year": "2020" }, { "DOI": "10.1038/s41586-020-2380-z", "author": "B Ju", "doi-asserted-by": "publisher", "first-page": "115", "journal-title": "Nature", "key": "753_CR14", "unstructured": "Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115–19.", "volume": "584", "year": "2020" }, { "DOI": "10.1016/j.clinthera.2021.08.009", "author": "JY Kim", "doi-asserted-by": "publisher", "first-page": "1706", "issue": "10", "journal-title": "Clin Ther", "key": "753_CR15", "unstructured": "Kim JY, Jang YR, Hong JH, et al. Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection. Clin Ther. 2021;43(10):1706–27.", "volume": "43", "year": "2021" }, { "author": "SM Hoy", "first-page": "1327", "issue": "12", "journal-title": "First Approval Drugs", "key": "753_CR16", "unstructured": "Hoy SM. Amubarvimab/Romlusevimab: first approval. Drugs. 2022;82(12):1327–31.", "volume": "82", "year": "2022" }, { "DOI": "10.1016/S1473-3099(21)00751-9", "author": "ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group", "doi-asserted-by": "publisher", "first-page": "622", "issue": "5", "journal-title": "Lancet Infect Dis", "key": "753_CR17", "unstructured": "ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022;22(5):622–35.", "volume": "22", "year": "2022" }, { "DOI": "10.1093/ofid/ofab466.1643", "doi-asserted-by": "crossref", "key": "753_CR18", "unstructured": "Evering TH, Mark G, Chew KW, et al. LB2. Safety and efficacy of combination SARS-CoV-2 monoclonal neutralizing antibodies (mAb) BRII-196 and BRII-198 in non-hospitalized COVID-19 patients[J]. Open Forum Infect Di. 2021." }, { "DOI": "10.1080/22221751.2022.2117094", "author": "JM Seo", "doi-asserted-by": "publisher", "first-page": "2315", "issue": "1", "journal-title": "Emerg Microbes Infect", "key": "753_CR19", "unstructured": "Seo JM, Kang B, Song R, et al. Preclinical assessment and randomized phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerg Microbes Infect. 2022;11(1):2315–25.", "volume": "11", "year": "2022" }, { "DOI": "10.1126/scitranslmed.abf1906", "author": "BE Jones", "doi-asserted-by": "publisher", "first-page": "eabf1906", "journal-title": "Sci Transl Med", "key": "753_CR20", "unstructured": "Jones BE, Brown-Augsburger PL, Corbett KS, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13:eabf1906.", "volume": "13", "year": "2021" }, { "DOI": "10.1126/science.abe2402", "author": "A Baum", "doi-asserted-by": "publisher", "first-page": "1110", "journal-title": "Science", "key": "753_CR21", "unstructured": "Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370:1110–5.", "volume": "370", "year": "2020" }, { "DOI": "10.1056/NEJMoa2107934", "author": "A Gupta", "doi-asserted-by": "publisher", "first-page": "1941", "issue": "21", "journal-title": "N Engl J Med", "key": "753_CR22", "unstructured": "Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–50.", "volume": "385", "year": "2021" } ], "reference-count": 22, "references-count": 22, "relation": {}, "resource": { "primary": { "URL": "https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00753-7" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "25" }